SCHEMBL4577412

SCHEMBL4577412

O=[N+]([O-])c1cc2c(Nc3ccc(F)cc3F)ncnc2cc1F

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.59
FLT1 P17948 4/20 0.59
FGFR1 P11362 2/20 0.59
ABCG2 Q9UNQ0 1/20 0.49
RAF1 P04049 1/20 0.47
BRAF P15056 1/20 0.47
EGFR P00533 10/20 0.47
RET P07949 1/20 0.46
KIF5B P33176 1/20 0.46
DYRK1A Q13627 1/20 0.46
EPHB2 P29323 1/20 0.46
FLT4 P35916 1/20 0.46
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
EPHA2 P29317 1/20 0.43
EPHB4 P54760 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4577295 0.89 EGFR (0.60) KDRABCG2EGFRRETKIF5B
SCHEMBL5097637 0.88 KDR (0.60) KDRFLT1FGFR1ABCG2RAF1
SCHEMBL4578156 0.86 ABCG2 (0.49) KDRFLT1FGFR1ABCG2RAF1
SCHEMBL4578621 0.85 EGFR (0.47) KDRFLT1FGFR1ABCG2EGFR
SCHEMBL4577926 0.84 KDR (0.58) KDRFLT1FGFR1ABCG2RAF1
SCHEMBL3239502 0.83 EGFR (0.59) KDRFLT1FGFR1ABCG2EGFR
SCHEMBL29719187 0.83 EGFR (0.50) KDRFLT1FGFR1ABCG2RAF1
SCHEMBL4577834 0.83 SRC (0.56) KDRFLT1FGFR1ABCG2RAF1
SCHEMBL4579881 0.83 EGFR (0.50) KDRABCG2EGFRRETKIF5B
SCHEMBL157980 0.83 EGFR (0.50) KDRFLT1FGFR1ABCG2RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846699-B2 Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof HANMI PHARM. CO., LTD. (KR) 2014-09-30 US disclosed
EP-1951686-B1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM IND CO LTD (KR) 2013-04-03 EP disclosed
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof HANMI PHARM. CO., LTD (KR) 2008-12-25 US disclosed
EP-1951686-A1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2008-08-06 EP disclosed
WO-2007055514-A1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof ABL1, JAK1, BTK KDR 1226/4885FLT1 959/4885FGFR1 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.